Morgan Stanley Gamida Cell Ltd. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Gamida Cell Ltd. stock. As of the latest transaction made, Morgan Stanley holds 1,292 shares of GMDA stock, worth $38. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,292

Previous 197,833 99.35%

Holding current value

$38

Previous $81,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.04 - $0.46 $7,861 - $90,408	-196,541 Reduced 99.35%	1,292 $0
Q4 2023 Feb 13, 2024	BUY	$0.25 - $1.02 $11,834 - $48,284	47,338 Added 31.45%	197,833 $81,000
Q3 2023 Nov 15, 2023	BUY	$0.85 - $1.87 $4,047 - $8,904	4,762 Added 3.27%	150,495 $155,000
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $31,928 - $103,659	43,738 Added 42.88%	145,733 $281,000
Q1 2023 May 15, 2023	SELL	$0.68 - $1.71 $16,396 - $41,233	-24,113 Reduced 19.12%	101,995 $82,000

Q4 2022 Feb 14, 2023	SELL	$1.15 - $2.1 $17,713 - $32,346	-15,403 Reduced 10.88%	126,108 $162,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.39 $24,103 - $53,406	15,754 Added 12.53%	141,511 $225,000
Q2 2022 Oct 27, 2022	BUY	$1.73 - $4.29 $2,302 - $5,709	1,331 Added 1.07%	125,757 $223,000
Q2 2022 Aug 15, 2022	BUY	$1.73 - $4.29 $2,302 - $5,709	1,331 Added 1.07%	125,757 $223,000
Q1 2022 Oct 27, 2022	SELL	$2.22 - $4.47 $2,954 - $5,949	-1,331 Reduced 1.06%	124,426 $517,000
Q1 2022 May 13, 2022	BUY	$2.22 - $4.47 $108,389 - $218,243	48,824 Added 64.58%	124,426 $517,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $22,523 - $45,661	10,238 Added 15.66%	75,602 $192,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $6.44 $251,651 - $420,944	65,364 New	65,364 $256,000

Others Institutions Holding GMDA

# of Institutions

Shares Held

11.4M

Call Options Held

235K

Put Options Held

70.5K

View Full List

About Gamida Cell Ltd.

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

More about GMDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account